ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 ANS Annual Conference
May 31–June 3, 2026
Denver, CO|Sheraton Denver
Latest Magazine Issues
Jan 2026
Jul 2025
Latest Journal Issues
Nuclear Science and Engineering
February 2026
Nuclear Technology
January 2026
Fusion Science and Technology
November 2025
Latest News
EDF fleet update has encouraging news for U.K. nuclear industry
The EDF Group’s Nuclear Operations business, which is the majority owner of the five operating and three decommissioning nuclear power plant sites in the United Kingdom, has released its annual update on the U.K. fleet. UK Nuclear Fleet Stakeholder Update: Powering an Electric Britain includes a positive review of the previous year’s performance and news of a billion-dollar boost in the coming years to maximize output across the fleet.
Hungyuan B. Liu, Francis J. Patti
Nuclear Technology | Volume 116 | Number 3 | December 1996 | Pages 373-377
Technical Note | Heat Transfer and Fluid Flow | doi.org/10.13182/NT96-A35292
Articles are hosted by Taylor and Francis Online.
Recent changes are updated for the proposed modification to use a fission plate converter and a matching filter/moderator assembly in a newly designed beam shutter to enhance the epithermal neutron beam for patient irradiations during boron neutron capture therapy (BNCT) at the Brookhaven Medical Research Reactor, Brookhaven National Laboratory. Engineering design of the new beam shutter system has been completed, and design review is under way. With this upgrade, the epithermal neutron flux could be increased up to seven times higher than the present beam, and the fast-neutron dose per epithermal neutron fluence could be reduced to near half. Such an enhanced epithermal neutron beam would increase the effectiveness of clinical BNCT by allowing increased doses to the tumor with similar or lesser doses to normal tissues.